GE HealthCare Announces Changes in Strategic Leadership and Key Segments to Better Serve Patients and Customers
10 Juin 2024 - 10:06PM
Business Wire
- Roland Rott, the current president and CEO of Ultrasound, will
lead Imaging, replacing Jan Makela
- Philip Rackliffe, the current president and CEO of Image Guided
Therapies (IGT), will lead Ultrasound and IGT
GE HealthCare (Nasdaq: GEHC) announced today that it has named
Roland Rott president and CEO of Imaging and Phil Rackliffe
president and CEO of Ultrasound and IGT. Both leaders bring to
their roles decades of deep experience in healthcare innovation and
experience leading global teams in businesses of scale. This also
highlights the depth of internal talent that GE HealthCare is
building to strengthen focus on delivering for patients and
customers. These changes will be effective July 1, 2024.
IGT, a $1.6 billion subsegment of Imaging, will be combined with
the Ultrasound segment in the third quarter of 2024, to form a
global business with more than $5.0 billion in annual revenue.i GE
HealthCare is aligning IGT with Ultrasound to better match its
clinical usage and realize stronger business and customer impact by
providing the right image guidance in the right care setting.
Aligning IGT and Ultrasound positions GE HealthCare to be more
agile and address future imaging needs using these real-time
modalities in both inpatient and outpatient settings.
Without IGT, Imaging will remain GE HealthCare’s largest segment
with more than $8.9 billion in annual revenue.ii This segment will
enhance focus on solutions centered on surgical and interventional
procedures, particularly interventional cardiology and structural
heart, while continuing Ultrasound’s diagnostic leadership.
Peter Arduini, chief executive officer of GE HealthCare, said,
“Roland and Phil will bring fresh viewpoints, global perspective,
and deep industry expertise to our Imaging segment and new
Ultrasound and IGT segment. Elevating leaders who have a deep
understanding of our customers’ needs, market trends, and our
strategic focus will help enable us to accelerate innovation and
growth. Roland and Phil are proven leaders who are well positioned
to take on these new opportunities, drive our precision care
strategy, and deliver for patients and customers.”
Roland joined GE Healthcare in 2011 and has held multiple
leadership roles within Ultrasound, ultimately becoming president
and CEO in 2021. He has a strong track record of growing healthcare
businesses at scale, and driving digital and artificial
intelligence (AI) in product innovation. He has been instrumental
in leading M&A activities including the BK Medical and Caption
Health acquisitions, and established strategic alliances with new
partners, such as the Bill & Melinda Gates Foundation and BARDA
and Novo Nordisk. He has delivered significant platforming results
in Ultrasound including the recently launched LOGIQ E10 Series and
LOGIQ Fortis and Voluson Signature ultrasound systems, and will
drive similar platforming efforts in Imaging. Before joining GE
HealthCare, Roland worked as an executive committee member at a
publicly traded company and founded two software companies that
were acquired by strategic investors.
Phil joined GE HealthCare in 2022 to lead IGT and has delivered
significant accretive revenue growth for the business during his
tenure. Since joining GE HealthCare, Phil has led R&D expansion
related to new product introductions including Allia Pulse,
3DStent, EmboAssist AI and OmnifyXR. He has also led strategic
equity investments focused on improving visualization and surgical
navigation techniques using technology such as augmented reality
during minimally invasive procedures. He has over two decades of
global experience in MedTech, Medical Devices and Pharmaceuticals
working for public companies, including Baxter Healthcare, Boston
Scientific, and Pfizer, as well as Ernst and Young. Phil’s last
role before joining GE HealthCare was CEO of Centerline Biomedical,
a spinout of Cleveland Clinic.
GE HealthCare expects to provide recast financial results to
reflect the movement of IGT from Imaging to the new Ultrasound and
IGT segment in its filings with the U.S. Securities and Exchange
Commission for third quarter 2024.
About GE HealthCare Technologies Inc. GE HealthCare is a
leading global medical technology, pharmaceutical diagnostics, and
digital solutions innovator, dedicated to providing integrated
solutions, services, and data analytics to make hospitals more
efficient, clinicians more effective, therapies more precise, and
patients healthier and happier. Serving patients and providers for
more than 125 years, GE HealthCare is advancing personalized,
connected, and compassionate care, while simplifying the patient’s
journey across the care pathway. Together our Imaging, Ultrasound,
Patient Care Solutions, and Pharmaceutical Diagnostics businesses
help improve patient care from diagnosis, to therapy, to
monitoring. We are a $19.6 billion business with approximately
51,000 colleagues working to create a world where healthcare has no
limits.
Follow us on LinkedIn, X (formerly Twitter), Facebook,
Instagram, and Insights for the latest news, or visit our website
https://www.gehealthcare.com/ for more information.
_________________________________
i
All stated revenues for IGT, Ultrasound
and Imaging are 2023 figures.
ii
All stated revenues for IGT, Ultrasound
and Imaging are 2023 figures.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240610228657/en/
Investor Relations Contact: Carolynne Borders
+1-631-662-4317 carolynne.borders@gehealthcare.com
Media Relations Contact: Jennifer Fox +1 414 530 3027
Jennifer.r.fox@gehealthcare.com
GE HealthCare Technologies (NASDAQ:GEHC)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
GE HealthCare Technologies (NASDAQ:GEHC)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024